| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 1191 | 1 | NAACCR/SEER | 2025 | 25 |
EWS-FLI1 fusion occurs in about 90% of Ewing Sarcomas and functions as both a pioneering transcription factor and potent oncogene.
This is part of the National Childhood Cancer Registry (NCCR) project to collect more specific information on pediatric patients. Registries part of the NCCR will start collection on specific pediatric data items with 2024+ diagnoses.
Source documents: molecular pathology report (may be addendum to original pathology report).
| 0 | No gene rearrangements (fusions) identified |
| 1 | EWSR1-FLI1 gene rearrangement (fusion) present |
| 2 | EWSR1-ERG gene rearrangement (fusion) present |
| 3 | Other EWSR1 gene rearrangement (fusion) present |
| 4 | EWSR1 rearrangement present, fusion partner not known |
| 5 | Non-EWSR1 variant translocation present |
| 7 | Test ordered, results not in chart |
| 8 | Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 8 may result in an edit error.) |
| 9 | Not documented in medical record Cannot be determined by pathologist EWSR1 gene arrangements not assessed or unknown if assessed |
Note 1: Effective years
Note 2: Physician statement